Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Oncology Institute (TOI) Accumulated Depreciation & Amortization (2020 - 2025)

Oncology Institute (TOI) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $5.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Depreciation & Amortization rose 15.98% year-over-year to $5.3 million, compared with a TTM value of $5.3 million through Sep 2025, up 15.98%, and an annual FY2024 reading of $6.3 million, up 7.05% over the prior year.
  • Accumulated Depreciation & Amortization was $5.3 million for Q3 2025 at Oncology Institute, up from $3.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $6.3 million in Q4 2024 and bottomed at $777000.0 in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $3.1 million, with a median of $3.0 million recorded in 2024.
  • The sharpest move saw Accumulated Depreciation & Amortization grew 5.13% in 2021, then surged 33.46% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $3.3 million in 2021, then surged by 32.03% to $4.4 million in 2022, then surged by 33.14% to $5.9 million in 2023, then grew by 7.05% to $6.3 million in 2024, then decreased by 15.51% to $5.3 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for TOI at $5.3 million in Q3 2025, $3.6 million in Q2 2025, and $1.8 million in Q1 2025.